152 related articles for article (PubMed ID: 10923075)
41. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
[TBL] [Abstract][Full Text] [Related]
42. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
43. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1.
Steube KG; Gignac SM; Hu ZB; Teepe D; Harms D; Kabisch H; Gaedicke G; Hansen-Hagge T; Macleod RA; Quentmeier H; Drexler HG
Leuk Lymphoma; 1997 Apr; 25(3-4):345-63. PubMed ID: 9168445
[TBL] [Abstract][Full Text] [Related]
44. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
46. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics.
San Miguel JF; Hernández JM; González-Sarmiento R; González M; Sánchez I; Orfao A; Cañizo MC; López Borrasca A
Blood; 1991 Aug; 78(3):768-74. PubMed ID: 1859889
[TBL] [Abstract][Full Text] [Related]
47. [Abnormality of immunophenotyping in patients with myelodysplastic syndrome].
Xu J; Guo YX; Zhao H; Hui WH; Wan SG; Sun XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):894-7. PubMed ID: 19698224
[TBL] [Abstract][Full Text] [Related]
48. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
49. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
50. [Study on the immunophenotypes of bone marrow cells from patients with myelodysplastic syndromes and its clinical implications].
Wang JY; Li XM; Li FJ; Chen XG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):173-4. PubMed ID: 12513825
[TBL] [Abstract][Full Text] [Related]
51. Immunophenotypic analysis of myelodysplastic syndromes.
Del Cañizo MC; Fernández ME; López A; Vidriales B; Villarón E; Arroyo JL; Ortuño F; Orfao A; San Miguel JF
Haematologica; 2003 Apr; 88(4):402-7. PubMed ID: 12681967
[TBL] [Abstract][Full Text] [Related]
52. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
53. Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).
Chen Z; Ok CY; Wang W; Goswami M; Tang G; Routbort M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2020 Jan; 98(1):36-42. PubMed ID: 31211490
[TBL] [Abstract][Full Text] [Related]
54. Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms.
Jevremovic D; Timm MM; Reichard KK; Morice WG; Hanson CA; Viswanatha DS; Howard MT; Nguyen PL
Am J Clin Pathol; 2014 Sep; 142(3):292-8. PubMed ID: 25125617
[TBL] [Abstract][Full Text] [Related]
55. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
Mihara K; Chowdhury M; Nakaju N; Hidani S; Ihara A; Hyodo H; Yasunaga S; Takihara Y; Kimura A
Blood; 2006 Jan; 107(1):305-8. PubMed ID: 16160010
[TBL] [Abstract][Full Text] [Related]
56. Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes.
Vikentiou M; Psarra K; Kapsimali V; Liapis K; Michael M; Tsionos K; Lianidou E; Papasteriades C
Leuk Lymphoma; 2009 Mar; 50(3):401-9. PubMed ID: 19294559
[TBL] [Abstract][Full Text] [Related]
57. CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis.
Elghetany MT; Patel J; Martinez J; Schwab H
Cytometry B Clin Cytom; 2003 Jan; 51(1):9-13. PubMed ID: 12500292
[TBL] [Abstract][Full Text] [Related]
58. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.
Zheng W; Medeiros LJ; Hu Y; Powers L; Cortes JE; Ravandi-Kashani F; Kantarjian HH; Wang SA
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):307-14. PubMed ID: 23313069
[TBL] [Abstract][Full Text] [Related]
59. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
60. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
